Below are the financial statements of Glenmark Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of INR | 2025 | 2024 |
|---|---|---|
| Income | — | — |
| Revenue from operations | 133,217.4a | 118,130.97a |
| Other income (net) | 1,137.22a | 8,399.94a |
| Total income | 134,354.62a | 126,530.91a |
| Expenses | — | — |
| Cost of materials consumed | -30,012.72a | -31,578.22a |
| Purchases of stock-in-trade | -15,660.03a | -14,511.7a |
| Changes in inventories of work-in-process, stock-in-trade and finished goods | -2,139.33a | -1,956.22a |
| Employee benefits expense | -30,220.61a | -28,681.43a |
| Finance costs | -2,070.65a | -5,159.69a |
| Depreciation, amortisation and impairment expense | -4,860.1a | -5,819.06a |
| Other expenses | -35,949.56a | -33,362.53a |
| Total expenses | -116,634.34a | -117,156.41a |
| Continuing operations | — | — |
| Profit before exceptional items and tax | 17,720.28a | 9,374.5a |
| Exceptional items - expense / (income) | 3,728.19a | 9,009.55a |
| Profit before tax from continuing operations | 13,992.09a | 364.95a |
| Tax expense | — | — |
| Current tax | -3,823.41a | -11,155.52a |
| Deferred tax | -302.74a | -7,517.93a |
| Total tax expense | -3,520.67a | -18,673.45a |
| Profit for the year from continuing operations | 10,471.42a | -18,308.5a |
| Attributable to | — | — |
| Non-controlling interest | 0.45a | 681.46a |
| Equity shareholders of Glenmark Pharmaceuticals Limited | 10,470.97a | -18,989.96a |
| Profit before tax from discontinued operations | 0a | 5,326.92a |
| Tax expense of discontinued operations | — | — |
| Current tax | 0a | -1,284.32a |
| Deferred tax | 0a | -69.32a |
| Total tax expense | 0a | -1,353.64a |
| Profit for the year from discontinued operations | 0a | 3,973.28a |
| Attributable to | — | — |
| Non-controlling interest | 0a | 0a |
| Equity shareholders of Glenmark Pharmaceuticals Limited | 0a | 3,973.28a |
| Profit/(loss) after tax for the period from continuing and discontinued operations | 10,471.42a | -14,335.22a |
| Non-controlling interest | 0.45a | 681.46a |
| Equity shareholders of Glenmark Pharmaceuticals Limited | 10,470.97a | -15,016.68a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Glenmark Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.